Contents

List of Contributors *XV*
About the Series Editors *XXIII*

1 **Integrative Analysis of Omics Data** *1*
Tobias Österlund, Marija Cvijovic, and Erik Kristiansson
Summary *1*
1.1 Introduction *1*
1.2 Omics Data and Their Measurement Platforms *4*
1.2.1 Omics Data Types *4*
1.2.2 Measurement Platforms *5*
1.3 Data Processing: Quality Assessment, Quantification, Normalization, and Statistical Analysis *6*
1.3.1 Quality Assessment *7*
1.3.2 Quantification *9*
1.3.3 Normalization *10*
1.3.4 Statistical Analysis *11*
1.4 Data Integration: From a List of Genes to Biological Meaning *12*
1.4.1 Data Resources for Constructing Gene Sets *13*
1.4.1.1 Gene Ontology Terms *13*
1.4.1.2 KEGG and Reactome *13*
1.4.1.3 Genome-Scale Metabolic Reconstructions *14*
1.4.2 Gene Set Analysis *14*
1.4.2.1 Gene Set Overenrichment Tests *16*
1.4.2.2 Rank-Based Enrichment Tests *16*
1.4.3 Networks and Network Topology *17*
1.5 Outlook and Perspectives *18*
References *19*

2 **^{13}C Flux Analysis in Biotechnology and Medicine** *25*
Yi Ern Cheah, Clinton M. Hasenour, and Jamey D. Young
2.1 Introduction *25*
2.1.1 Why Study Metabolic Fluxes? *25*
2.1.2 Why are Isotope Tracers Important for Flux Analysis? *26*

2.1.3 How are Fluxes Determined? *28*
2.2 Theoretical Foundations of ^{13}C MFA *29*
2.2.1 Elementary Metabolite Units (EMUs) *30*
2.2.2 Flux Uncertainty Analysis *31*
2.2.3 Optimal Design of Isotope Labeling Experiments *32*
2.2.4 Isotopically Nonstationary MFA (INST-MFA) *34*
2.3 Metabolic Flux Analysis in Biotechnology *36*
2.3.1 ^{13}C MFA for Host Characterization *36*
2.3.2 ^{13}C MFA for Pinpointing Yield Losses and Futile Cycles *39*
2.3.3 ^{13}C MFA for Bottleneck Identification *41*
2.4 Metabolic Flux Analysis in Medicine *42*
2.4.1 Liver Glucose and Oxidative Metabolism *43*
2.4.2 Cancer Cell Metabolism *47*
2.4.3 Fuel Oxidation and Anaplerosis in the Heart *48*
2.4.4 Metabolism in Other Tissues: Pancreas, Brain, Muscle, Adipose, and Immune Cells *49*
2.5 Emerging Challenges for ^{13}C MFA *50*
2.5.1 Theoretical and Computational Advances: Multiple Tracers, Co-culture MFA, Dynamic MFA *50*
2.5.2 Genome-Scale ^{13}C MFA *51*
2.5.3 New Measurement Strategies *52*
2.5.4 High-Throughput MFA *53*
2.5.5 Application of MFA to Industrial Bioprocesses *53*
2.5.6 Integrating MFA with Omics Measurements *54*
2.6 Conclusion *55*
Acknowledgments *55*
Disclosure *55*
References *55*

3 Metabolic Modeling for Design of Cell Factories *71*
Mingyuan Tian, Prashant Kumar, Sanjan T. P. Gupta, and Jennifer L. Reed
Summary *71*
3.1 Introduction *71*
3.2 Building and Refining Genome-Scale Metabolic Models *72*
3.2.1 Generate a Draft Metabolic Network (Step 1) *74*
3.2.2 Manually Curate the Draft Metabolic Network (Step 2) *75*
3.2.3 Develop a Constraint-Based Model (Step 3) *77*
3.2.4 Revise the Metabolic Model through Reconciliation with Experimental Data (Step 4) *79*
3.2.5 Predicting the Effects of Genetic Manipulations *81*
3.3 Strain Design Algorithms *83*
3.3.1 Fundamentals of Bilevel Optimization *84*
3.3.2 Algorithms Involving Only Gene/Reaction Deletions *94*
3.3.3 Algorithms Involving Gene Additions *94*
3.3.4 Algorithms Involving Gene Over/Underexpression *95*

3.3.5 Algorithms Involving Cofactor Changes *98*
3.3.6 Algorithms Involving Multiple Design Criteria *99*
3.4 Case Studies *100*
3.4.1 Strains Producing Lactate *100*
3.4.2 Strains Co-utilizing Sugars *100*
3.4.3 Strains Producing 1,4-Butanediol *102*
3.5 Conclusions *103*
Acknowledgments *103*
References *104*

4 Genome-Scale Metabolic Modeling and *In silico* Strain Design of *Escherichia coli* *109*
Meiyappan Lakshmanan, Na-Rae Lee, and Dong-Yup Lee
4.1 Introduction *109*
4.2 The COBRA Approach *110*
4.3 History of *E. coli* Metabolic Modeling *111*
4.3.1 Pre-genomic-era Models *111*
4.3.2 Genome-Scale Models *112*
4.4 *In silico* Model-Based Strain Design of *E. coli* Cell Factories *115*
4.4.1 Gene Deletions *127*
4.4.2 Gene Up/Downregulations *127*
4.4.3 Gene Insertions *128*
4.4.4 Cofactor Engineering *128*
4.4.5 Other Approaches *128*
4.5 Future Directions of Model-Guided Strain Design in *E. coli* *129*
References *130*

5 Accelerating the Drug Development Pipeline with Genome-Scale Metabolic Network Reconstructions *139*
Bonnie V. Dougherty, Thomas J. Moutinho Jr., and Jason Papin
Summary *139*
5.1 Introduction *139*
5.1.1 Drug Development Pipeline *140*
5.1.2 Overview of Genome-Scale Metabolic Network Reconstructions *140*
5.1.3 Analytical Tools and Mathematical Evaluation *141*
5.1.3.1 Flux Balance Analysis (FBA) *141*
5.1.3.2 Flux Variability Analysis (FVA) *142*
5.2 Metabolic Reconstructions in the Drug Development Pipeline *142*
5.2.1 Target Identification *143*
5.2.2 Drug Side Effects *145*
5.3 Species-Level Microbial Reconstructions *146*
5.3.1 Microbial Reconstructions in the Antibiotic Development Pipeline *146*
5.3.1.1 Applications in the Drug Development Pipeline *146*

5.3.2 Metabolic-Reconstruction-Facilitated Rational Drug Target Identification *147*
5.3.2.1 Targeting Genes Essential for Biomass Production *147*
5.3.2.2 Targeting Virulence Factors *147*
5.3.2.3 Metabolite-centric Targeting *148*
5.3.3 Repurposing and Expanding Utility of Antibiotics *149*
5.3.3.1 Virtual Drug Screens Informed by Metabolic Reconstructions *149*
5.3.3.2 Limiting Resistance with Drug Combinations *149*
5.3.3.3 Improving Treatment Options by Increasing Sensitivity to Antibiotics *150*
5.3.4 Improving Toxicity Screens with the Human Metabolic Network Reconstruction *150*
5.4 The Human Reconstruction *151*
5.4.1 Approaches for the Human Reconstruction *152*
5.4.2 Target Identification *152*
5.4.2.1 Drug Targeting in Cancer *152*
5.4.2.2 Drug Targeting in Metabolic Diseases *153*
5.4.3 Toxicity and Other Side Effects *154*
5.5 Community Models *155*
5.5.1 Host–Pathogen Community Models *155*
5.5.2 Eukaryotic Community Models *156*
5.6 Personalized Medicine *156*
5.7 Conclusion *157*
References *158*

6 Computational Modeling of Microbial Communities *163*
Siu H. J. Chan, Margaret Simons, and Costas D. Maranas
Summary *163*
6.1 Introduction *163*
6.1.1 Microbial Communities *163*
6.1.2 Modeling Microbial Communities *165*
6.1.3 Model Structures *165*
6.1.4 Quantitative Approaches *166*
6.2 Ecological Models *168*
6.2.1 Generalized Predator–Prey Model *169*
6.2.2 Evolutionary Game Theory *170*
6.2.3 Models Including Additional Dimensions *171*
6.2.4 Advantages and Disadvantages *171*
6.3 Genome-Scale Metabolic Models *172*
6.3.1 Introduction and Applications *172*
6.3.2 Genome-Scale Metabolic Modeling of Microbial Communities *174*
6.3.3 Simulation of Microbial Communities Assuming Steady State *175*
6.3.3.1 Predicting Interactions Using FBA *175*
6.3.3.2 Identifying Minimal Media by Mixed Integer Linear Programming *176*

6.3.3.3 Pareto Optimality Analysis by FBA *176*
6.3.3.4 Modeling Chemostat Co-culture *177*
6.3.3.5 Community FBA with Community Mass Balance *177*
6.3.4 Dynamic Simulation of Multispecies Models *177*
6.3.5 Spatial and Temporal Modeling of Communities *178*
6.3.6 Using Bilevel Optimization to Capture Multiple Objective Functions *179*
6.3.6.1 OptCom *179*
6.3.6.2 d-OptCom *181*
6.3.6.3 CASINO Toolbox *181*
6.3.6.4 Advantages and Disadvantages *182*
6.3.6.5 Current Challenges and Future Directions *182*
6.4 Concluding Remarks *183*
References *183*

7 Drug Targeting of the Human Microbiome *191*
Hua Ling, Jee L. Foo, Gourvendu Saxena, Sanjay Swarup, and Matthew W. Chang
Summary *191*
7.1 Introduction *191*
7.2 The Human Microbiome *192*
7.3 Association of the Human Microbiome with Human Diseases *194*
7.3.1 Nasal–Sinus Diseases *194*
7.3.2 Gut Diseases *194*
7.3.3 Cardiovascular Diseases *196*
7.3.4 Metabolic Disorders *196*
7.3.5 Autoimmune Disorders *197*
7.3.6 Lung Diseases *197*
7.3.7 Skin Diseases *197*
7.4 Drug Targeting of the Human Microbiome *198*
7.4.1 Prebiotics *198*
7.4.2 Probiotics *200*
7.4.3 Antimicrobials *201*
7.4.3.1 Antibiotics *201*
7.4.3.2 Antimicrobial Peptides *202*
7.4.4 Signaling Inhibitors *202*
7.4.5 Metabolites *203*
7.4.5.1 Short-Chain Fatty Acids *203*
7.4.5.2 Bile Acids *203*
7.4.6 Metabolite Receptors and Enzymes *204*
7.4.6.1 Metabolite Receptors *204*
7.4.6.2 Metabolic Enzymes *204*
7.4.7 Microbiome-Aided Drug Metabolism *205*
7.4.7.1 Drug Delivery and Release *205*

7.4.7.2 Drug Toxicity *206*
7.4.8 Immune Modulators *206*
7.4.9 Synthetic Commensal Microbes *207*
7.5 Future Perspectives *207*
7.6 Concluding Remarks *208*
Acknowledgments *208*
References *209*

8 Toward Genome-Scale Models of Signal Transduction Networks *215*
Ulrike Münzner, Timo Lubitz, Edda Klipp, and Marcus Krantz
8.1 Introduction *215*
8.2 The Potential of Network Reconstruction *219*
8.3 Information Transfer Networks *222*
8.4 Approaches to Reconstruction of ITNs *225*
8.5 The rxncon Approach to ITNWR *230*
8.6 Toward Quantitative Analysis and Modeling of Large ITNs *234*
8.7 Conclusion and Outlook *236*
Acknowledgments *236*
Glossary *237*
References *238*

9 Systems Biology of Aging *243*
Johannes Borgqvist, Riccardo Dainese, and Marija Cvijovic
Summary *243*
9.1 Introduction *243*
9.2 The Biology of Aging *245*
9.3 The Mathematics of Aging *249*
9.3.1 Databases Devoted to Aging Research *249*
9.3.2 Mathematical Modeling in Aging Research *249*
9.3.3 Distribution of Damaged Proteins during Cell Division: A Mathematical Perspective *256*
9.3.3.1 Cell Growth *256*
9.3.3.2 Cell Death *257*
9.3.3.3 Cell Division *257*
9.4 Future Challenges *260*
Conflict of Interest *262*
References *262*

10 Modeling the Dynamics of the Immune Response *265*
Elena Abad, Pablo Villoslada, and Jordi García-Ojalvo
10.1 Background *265*
10.2 Dynamics of NF-κB Signaling *266*
10.2.1 Functional Role and Regulation of NF-κB *266*

10.2.2 Dynamics of the NF-κB Response to Cytokine Stimulation *267*
10.3 JAK/STAT Signaling *273*
10.3.1 Functional Roles of the STAT Proteins *273*
10.3.2 Regulation of the JAK/STAT Pathway *274*
10.3.3 Multiplicity and Cross-talk in JAK/STAT Signaling *275*
10.3.4 Early Modeling of STAT Signaling *276*
10.3.5 Minimal Models of STAT Activation Dynamics *277*
10.3.6 Cross-talk with Other Immune Pathways *279*
10.3.7 Population Dynamics of the Immune System *281*
10.4 Conclusions *282*
Acknowledgments *283*
References *283*

11 Dynamics of Signal Transduction in Single Cells Quantified by Microscopy *289*
Min Ma, Nadim Mira, and Serge Pelet
11.1 Introduction *289*
11.2 Single-Cell Measurement Techniques *291*
11.2.1 Flow Cytometry *291*
11.2.2 Mass Cytometry *291*
11.2.3 Single-Cell Transcriptomics *292*
11.2.4 Single-Cell Mass Spectrometry *292*
11.2.5 Live-Cell Imaging *292*
11.3 Microscopy *293*
11.3.1 Epi-Fluorescence Microscopy *294*
11.3.2 Fluorescent Proteins *295*
11.3.3 Relocation Sensors *295*
11.3.4 Förster Resonance Energy Transfer *298*
11.4 Imaging Signal Transduction *300*
11.4.1 Quantifying Small Molecules *300*
11.4.2 Monitoring Enzymatic Activity *301*
11.4.2.1 Endogenous Relocation Sensors *301*
11.4.2.2 Passive Relocation Sensors *302*
11.4.2.3 Active Relocation Sensors *303*
11.4.2.4 FRET Biosensors *304*
11.4.3 Probing Protein–Protein Interactions *304*
11.4.3.1 FRET in Protein Complexes *304*
11.4.3.2 Bimolecular Fluorescence Complementation *305*
11.4.3.3 Dimerization-Dependent FP *306*
11.4.4 Measuring Protein Synthesis *307*
11.4.4.1 mRNA Transcription *307*
11.4.4.2 Protein Synthesis *308*
11.4.4.3 Expression Dynamics Visualized by Protein Relocation *311*

11.5 Conclusions *311*
References *312*

12 Image-Based *In silico* Models of Organogenesis *319*
Harold F. Gómez, Lada Georgieva, Odysse Michos, and Dagmar Iber
Summary *319*
12.1 Introduction *319*
12.2 Typical Workflow of Image-Based *In silico* Modeling Experiments *320*
12.2.1 *In silico* Models of Organogenesis *322*
12.2.2 Imaging as a Source of (Semi-)Quantitative Data *323*
12.2.2.1 Imaging a Growing Organ *324*
12.2.3 Image Analysis and Quantification *326*
12.2.4 Computational Simulations of Models Describing Organogenesis *328*
12.2.5 Image-Based Parameter Estimation *329*
12.2.6 *In silico* Model Validation and Exchange *329*
12.2.6.1 *In silico* Model Validation *329*
12.2.6.2 Model Exchange via the Systems Biology Markup Language (SBML) *330*
12.3 Application: Image-Based Modeling of Branching Morphogenesis *331*
12.3.1 Image-Based Model Selection *331*
12.4 Future Avenues *334*
References *334*

13 Progress toward Quantitative Design Principles of Multicellular Systems *341*
Eduardo P. Olimpio, Diego R. Gomez-Alvarez, and Hyun Youk
Summary *341*
13.1 Toward Quantitative Design Principles of Multicellular Systems *341*
13.2 Breaking Multicellular Systems into Distinct Functional and Spatial Modules May Be Possible *342*
13.3 Communication among Cells as a Means of Cell–Cell Interaction *346*
13.4 Making Sense of the Combinatorial Possibilities Due to Many Ways that Cells Can Be Arranged in Space *350*
13.5 From Individual Cells to Collective Behaviors of Cell Populations *352*
13.6 Tuning Multicellular Behaviors *355*
13.7 A New Framework for Quantitatively Understanding Multicellular Systems *359*
Acknowledgments *361*
References *362*

14 **Precision Genome Editing for Systems Biology – A Temporal Perspective** *367*
Franziska Voellmy and Rune Linding
Summary *367*
14.1 Early Techniques in DNA Alterations *367*
14.2 Zinc-Finger Nucleases *369*
14.3 TALENs *369*
14.4 CRISPR-Cas9 *370*
14.5 Considerations of Gene-Editing Nuclease Technologies *372*
14.5.1 Repairing Nuclease-Induced DNA Damage *372*
14.5.2 Nuclease Specificity *373*
14.6 Applications *376*
14.6.1 CRISPR Nuclease Genome-Wide Loss-of-Function Screens (CRISPRn) *377*
14.6.2 CRISPR Interference: CRISPRi *378*
14.6.3 CRISPR Activation: CRISPRa *378*
14.6.4 Further Scalable Additions to the CRISPR-Cas Gene Editing Tool Arsenal *379*
14.6.5 *In vivo* Applications *379*
14.6.5.1 Animal Disease Models *379*
14.6.5.2 Gene Therapy *379*
14.7 A Focus on the Application of Genome-Engineering Nucleases on Chromosomal Rearrangements *380*
14.7.1 Introduction to Chromosomal Rearrangements: The First Disease-Related Translocation *380*
14.7.2 A Global Look at the Mechanisms behind Chromosomal Rearrangements *382*
14.7.3 Creating Chromosomal Rearrangements Using CRISPR-Cas *383*
14.8 Future Perspectives *384*
References *384*

Index *393*